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Abstract
Background: The four types of human parainfluenza viruses (PIV) are important causes of community-acquired
pneumonia, particularly in children; however, limited information exists about the incidence of PIV in critically ill
patients. The aim of this study is to describe the spectrum, incidence and clinical features of PIV-associated
infections diagnosed during the hospital stay of patients admitted to pediatric intensive care unit (PICU) and
intensive care unit (ICU) of 5 medical centers across Kuwait.
Methods: This was a population-based, retrospective study from 2013 to 2015. Specimens were analyzed by
molecular methods. This analysis was performed using the database of Virology Unit, Mubarak Al-Kabeer Hospital.
Data from 1510 admitted patients with suspected respiratory viral infections was extracted.
Results: The database contained a total of 39 (2.6%) patients infected with PIV (53.8% male and 46.2% females) and
20 (51.3%) were under 1 year of age. The most frequently isolated type was type 3 (28, 71.8%) followed by type 1
(9, 23.1%). At admission the most common clinical diagnosis was pneumonia in 12 patients (30.8%, p < 0.05)
followed by bronchiolitis in 10 patients (25.6%).
Conclusion: PIV plays an important yet unrecognized role in the outcomes of PIUC and ICU patients. Our results
contribute to the limited epidemiologic data of PIV in PIUC and ICU in this region.
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Background
Viral infections are ubiquitous and are common in patients
admitted to intensive care unit (ICU) and pediatric inten-
sive care unit (PICU) and may be associated with signifi-
cant morbidity and mortality [1]. The vast majority of
scientific articles dealing with infections address bacterial
or fungal infections, and viral agents are often disregarded.
Despite their prevalence, viral infections are frequently not
considered to be of clinical significance among the critic-
ally ill patients, unless the patient is immunocompromised.
Among immunocompetent critically ill patients, viral infec-
tions can lead to a significant morbidity and mortality [2].
Parainfluenza viruses (PIV) were first discovered in
1950. They are enveloped non-segmented, negative
single-stranded RNA viruses. PIV are genetically and
antigenically divided into four types: PIV-1, PIV-2, PIV-
3 and PIV-4, each with different genetic and antigenic
features [3]. PIV are a cause of community-acquired
pneumonia in healthy individuals and can infect indi-
viduals of any age group [4–6]. The majority of PIV-
infected patients are treated in outpatient clinics, yet
PIV infections are one of the most common causes of
respiratory diseases leading to hospitalization [4, 5, 7].
Among the immunocompromised patients, PIV espe-
cially type 3 has been associated with serious outcomes
and complications [8]. PIV can also be clinically signifi-
cant in ICU and PICU patients [9, 10]. However, not
much is known about the burden of PIV infections
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among ICU and PICU patients. Such data are essential
because they could shed light on the importance of
these infections and could help researchers and public
health officials determine the need for new vaccines
and effective antiviral drugs. Until now, no specific
antiviral drugs or effective vaccine are available despite
the progress made in these fields recently [11–13]. The
aim of this study was to evaluate the possible effect of
PIV infections on ICU and PICU patients in Kuwait, in
addition to defining the clinical features of PIV infec-
tions among these patients over a 3-year period.
Methods
Patient records from the Virology Unit (VU), Faculty of
Medicine, Kuwait University Database, were retrospect-
ively reviewed to identify patients with viral infections
admitted to the PICU & ICU from January 2013 to
December 2015. The VU is an academic institution
serving five hospitals in Kuwait (Amiri Hospital,
Mubarak Al-Kabir Hospital, Sabah Hospital, Farwaniya
Hospital, and Adan Hospital).
Database and study population
Only Patients with viral infections were included in this
study. Data extracted from the records included demo-
graphic characteristics, clinical diagnosis, immune defi-
ciency, and number and types of viruses isolated. As this
study was retrospective, it did not require ethical ap-
proval. These patients were investigated for bacterial,
fungal and parasitic pathogens to rule out infection and
co-infection. No bacterial, fungal and parasitic pathogens
were detected in these patients.
All PIV-infected patients were immunocompetent
which was defined as the absence of organ transplant-
ation, human immunodeficiency virus (HIV) or acquired
immunodeficiency syndrome (AIDS), autoimmune dis-
ease, leukemia, pancytopenia, lymphoma or under im-
munosuppressive drug therapy. All patients underwent a
respiratory virus panel screening. Respiratory system
samples (bronchoalveolar lavage or tracheal aspirate)
were collected in disposable mucus extractors (Vygon
SA, Écouen, France). Samples were assayed by reverse
transcriptase-polymerase chain reaction (RT-PCR) to
detect 20 respiratory pathogen which include: influenza
virus A (Flu A), influenza virus A H1N1 (H1N1), influ-
enza virus B (Flu B), human coronavirus (HCoV)-NL63,
-229E, -OC43 and HKU1, PIV-1, -2, -3, -4 human
metapneumovirus (hMPV)-A and -B, rhinovirus (HRV),
respiratory syncytial virus (RSV)-A and B, adenovirus
(AdV), enterovirus (EV), parechovirus (HPeV), human
bocavirus (HBoV), using FTD® Respiratory Pathogens kit
(Fast-Track Diagnostics Ltd., Sliema, Malta).
Inclusion and exclusion criteria
Viral studies were not taken routinely and were
undertaken only on a clinical basis in patients with
suspected viral infections. The patients were divided
into three groups: 1) individuals with single docu-
mented viral infection during their hospitalization
(single); 2) those that were diagnosed with double
viral infections during their hospitalization (double);
and, 3) those that were diagnosed with triple or more
viral infections during their hospitalization (triple).
The double and triple infections were detected simul-
taneously from the same clinical sample provided.
Statistical analysis
Data analysis was performed using the Statistical Pack-
age for the Social Sciences software (SPSS v20.0; IBM
Corp, Armonk, N.Y. USA). Descriptive statistics for
continuous variables were compared using the non-
parametric Mann-Whitney U test or the Kruskal-
Wallis test. For categorical variables, the χ2 test, the
Fisher exact test or the Z test was applied to evaluate
the difference between proportions or to assess
whether there were any associations between the pro-
portions. A two-tailed probability value p < 0.05 was
considered statistically significant.
Results
Table 1 shows the demographic characteristics and clin-
ical parameters of 1510 patients admitted to ICU
(37.5%) and PICU (62.5%) with viral infections. A total
of 39 (2.6%) patients were found to have confirmed PIV
infections, with 21 (1.4%) in ICU and 18 (1.2%) in
PICU. The most frequently isolated PIV type was type
3 (28, 71.8%) followed by type 1 (9, 23.1%). The least
frequently isolated PIV type was type 4 (2, 5.1%), and
type 2 was not detected. Single infections were identi-
fied in 26 patients (66.6%), double co-infection in 9
patients (23.1%) and triple co-infection in 4 patients
(10.3%). For double co-infection category, the most fre-
quently isolated virus with PIV was HRV (n = 6; 15.4%)
followed by Flu A, AdV, and RSV (n = 1; 2.3% each).
For triple co-infection category, Flu A and HRV were
identified in all four patients.
The age of the patients ranged from 4 days to 71 years
with a mean of 14.6 ± 23.4 years and Median (Inter-
Quartile) is 7 months (2 months–24.5 years) (Table 2).
Table 1 shows age grouping of the study population
according to sex. The male to female ratio was 1.2:1.
PIV infections were identified in 20 (51.3%) of in-
fants below 1 year of age, 4 (10.3%) below 5 years of
age, 7 (18%) patients below 14 years of age, 7 (18%)
patients below 59 years of age and 5 (12.8%) ≥59 years
of age (Table 3). The most affected age group was
infants’ ≤5 months of age 18 (46.2%).
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Table 4 shows frequency of PIV types in the 39 ICU and
PICU patients in relation to symptoms. The majority of
the infections caused by the PIV types affected the
lower respiratory tract (35 patients, 89.7%) than the
upper respiratory tract (2 patients, 5.1%). Pneumonia
was the most frequent reason for hospitalization (12
patients, 30.8%), P < 0.05, followed by bronchiolitis (10
patients, 25.6%) and chronic obstructive pulmonary
disease (COPD) (7 patients, 18%).
The monthly distribution of PIV infections was highest
during the period from April to May and November to
December. The lowest levels were detected in February
and August (Fig. 1). The incidence of PIV infections in
ICU patients was highest during the months of April
and December and PICU patients during the month of
May and November. Infection in ICU patients peaked in
April (18.2%) and PICU patients in November (13.6%).
The monthly distribution of PIV infections according
to the types isolated is shown in Fig. 2. The incidence of
PIV-1 peaked in April (7 patients, 18%), followed by
May, November, and December (5 patients, 12.8% each).
PIV-3 was present throughout the year except in February
and August. The incidence of PIV-3 peaked in April and
November (13 patients, 33.3% each), followed by July and
December (7 patients, 18% each).
Discussion
This is a population-based retrospective study aimed
at characterizing the impact of PIV infections among
infants, children and adults admitted to the PICU and
ICU in 5 centers across Kuwait over a 3-year period.
This study was performed within five centers to give
it a potential strength, which emphasizes on the
generalizability of the results for the whole country.
Our data highlighted the importance of PIV as a
significant cause of respiratory tract infections and
disease in ICU and PICU patients which should not
be overlooked by both physicians and public health
officials. As we found in Kuwait, PIV infections were
identified among 2.6% of all ICU and PICU
admissions, 1.4% among ICU and 1.2% among PICU
patients. Multiple studies from across the world have
found that PIV is associated with hospitalization of
patients with respiratory tract infections, such as
those from Kuwait [14], Saudi Arabia [15]; Jordon
[16]; United States [17, 18], China [19, 20], Thailand
[21], Iran [22], Bangladesh [23], Kenya [24], South
Korea [9], Mexico [25] and Brazil [26]. Although, PIV
are considered as a significant causative agents of
both upper respiratory tract infections (URTI) and
lower respiratory tract infections (LRTI) in infants
and young children [3, 12, 27], the importance of
these viruses has been underestimated [28].
Previous studies have described different incidences
of PIV infections, but these studies involved different
study populations and used different detection tech-
niques. A study from Saudi Arabia, investigated the
incidence of PIV in hospitalized infants, children aged
up to 10 years only during the winter season by direct
immunofluorescence assay documented PIV infections
in 15.6% of hospitalized patients [15]. In another study
by Peltola et al. [29], exploring the etiology of croup in
hospitalized children, documented PIV-1, in 29.1% of
patients. A study from Spain, involving hospitalized
Table 2 Age groups of study population according to gender
Age (years) Mean ± SD Median (Inter-Quartile) Range
Male 19.0 ± 25.9 1 year (52 days–41.5 years) 4 days–71 years
Female 7.2 ± 16.9 4 months (55 days–6.5 years) 21 days–70 years
Overall 14.6 ± 23.4 7 months (2 months–24.5 years) 4 days–71 years






Overall Patients Tested 566 (37.5)a 944 (62.5)a 1510
PIV-positive 21 (53.9)a 18 (46.1)a 39 (2.6)a
Sex
Male 17 (43.5) 4 (10.3) 21 (53.8)b
Female 7 (17.9) 11 (28.2) 18 (46.2)b
Isolation
PIV-1 7 (18) 2 (5.1) 9 (23.1)b
PIV-2 0 0 0
PIV-3 14 (35.9) 14 (35.9) 28 (71.8)b
PIV-4 2 (5.1) 0 2 (5.1)b
Mixed infection
Single 14 (35.9) 12 (30.8) 26 (66.6)b
Double 6 (15.4) 3 (7.7) 9 (23.1)b
HRV 4 (10.3) 2 (5.1) 6 (15.4)b
FluA 1 (2.3) 0 1 (2.3)b
AdV 1 (2.3) 0 1 (2.3)b
RSV 0 1 (2.3) 1 (2.3)b
Triple 2 (5.1) 2 (5.1) 4 (10.3)b
HRV 2 (5.1) 2 (5.1) 4 (10.3)b
FluA 2 (5.1) 2 (5.1) 4 (10.3)b
aThe number in parentheses represents % of patients tested in relation to the
total number of patients tested (n = 1510)
bThe number in parentheses represents the number of PIV infections in
relation to the total number of PIV infections (n = 39)
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children aged up to 14 years with acute respiratory
tract infections, PIV infections accounting for 11.8% of
the positive cases [30]. In a study from Brazil aiming to
define the etiology of community-acquired pneumonia
in hospitalized children younger than 5 years, PIV
infections were detected in 3.81%, ranked third among
the most dominant viral agents [31].
As documented by Oh [32], we found that children
under 5 years of age had greater hospitalization rates,
possibly because their respiratory and immune sys-
tems are immature, predisposing to severe respiratory
tract infections/disease [32]. In this study, the chance
of isolating PIV-1, PIV-3, or PIV-4 in PICU patients aged
5 months or younger (46.2%) was three times higher than
that in children between 6 months to 4 years of age
(15.4%). However, our study showed that 28.2% of
PIV-infected ICU patients were older than 30 years.
Mixed viral infections were detected in our study with
33.3% (13/39) of positive cases with co-infections. This rate
is higher than those previously described in which co-
infection rates ranged from 3 to 20% [31, 33–37]. Earlier
studies have described the different incidence of mixed in-
fections probably due to dissimilar study populations and
detection techniques. Additional research is essential to
address high rates of mixed-infections with other respira-
tory viruses and to decide if the mixed-infections could
result in enhanced severity of PIV infections. In young chil-
dren, PIV infections are the most common cause of croup,
bronchiolitis and pneumonia [6, 38, 39]. In ICU patients,
COPD and bronchitis seem to be the most prominent
symptoms. PIV, are frequently detected in COPD and
bronchitis in the adult population [40–43].
There are four serotypes each with different genetic
and antigenic properties, and they vary in clinical pic-
ture, incidence, and seasonality [44, 45]. We showed
the presence of the three types of PIV infections in
Kuwait among ICU and PICU patients, including PIV-
4, which was identified for the first time during 2013–
2015. PIV-4 has been associated with mild infections
[46, 47]. Other studies have shown that it can cause
severe illnesses in some settings [48–50]. Though,
none of these studies from our region describe the
presence of PIV-4 [15, 16, 22]. The incidence of PIV-3
was higher than those of PIV-1 and PIV-4 in this
study, as found in other studies [30, 51–53], whereas
PIV-2 was not detected. It is documented that PIV-3 is
the type most commonly identified in hospitalized
patients with pneumonia and bronchiolitis [3, 54].
Table 3 Age groups according to PIV types in 39 patients
Age group PIV-1 No. (%) PIV-2 No. (%) PIV-3 No. (%) PIV-4 No. (%) Total No. (%)
≤1 M* 0 0 7 (7.7) 1 (2.6) 8 (20.5)
2–5 M 2 (5.1) 0 8 (26.5) 0 10 (25.6)
6–11 M 0 0 2 (5.1) 0 2 (5.1)
1–4 Y** 1 (2.6) 0 2 (5.1) 1 (2.6) 4 (10.3)
5–14 Y 1 (2.6) 0 2 (5.1) 0 3 (7.7)
15–29 Y 0 0 1 (2.6) 0 1 (2.6)
30–44 Y 3 (7.7) 0 1 (2.6) 0 4 (10.3)
45–59 Y 1 (2.6) 0 1 (2.6) 0 2 (5.1)
≥60 Y 1 (2.6) 0 4 (10.3) 0 5 (12.8)
All ages 9 (23.1) 0 28 (71.8) 2 (5.1) 39
*M=Month(s)
**Y=Year(s)
Table 4 Frequency of PIV types in 39 ICU and PICU patients in relation to symptom presentation
ICU Patients No. (%) PICU Patients No. (%) Total
PIV-1 PIV-3 PIV-4 Total PIV-1 PIV-3 PIV-4 Total
Pneumonia 4 (10.3) 0 0 4 (10.3) 0 8 (20.5) 0 8 (20.5) 12 (30.8)*
Bronchiolitis 0 4 (10.3) 0 4 (10.3) 2 (5.1) 4 (10.3) 0 6 (15.4) 10 (25.6)
aCOPD 3 (7.7) 4 (10.3) 0 7 (18) 0 0 0 0 7 (18)
Bronchitis 0 (10.3) 2 (5.1) 6 (15.4) 0 0 0 0 6 (15.4)
Laryngitis 0 0 0 0 0 2 (5.1) 0 2 (5.1) 2 (5.1)
Fever, Sepsis 0 0 0 0 0 2 (5.1) 0 2 (5.1) 2 (5.1)
aCOPD: Chronic obstructive pulmonary disease
*P < 0.05
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Outbreaks of respiratory virus infections in countries
with meditation or desert climates were documented
during the cold season, whereas in tropical countries,
they seem to be more associated with the rainy period
[55]. The seasonal occurrences of PIV types differ
from place to place, an outcome attributed to climatic
changes [31]. In a study from Saudi Arabia, Only PIV-
3 infection was detected all year round, but epidemics
occurred during summer (June–August) [56]. In the
USA, biannual patterns were described for PIV-1 and
annual peaks for PIV-3 [53, 57]. The seasonal incidence
of PIV-1 and PIV-3 among critically ill patients in Kuwait
occurred twice-a-year during autumn (April to May) and
winter (November to December), and once-a-year during
winter (January to December) for PIV-4 (Fig. 2).
Conclusion
This study highlighted the importance of PIV as a causa-
tive agent of respiratory tract infection in critically ill
patients, mainly in developing countries, where few data
concerning respiratory viruses are available. Further
studies may better define the burden of PIV infections
and the need for effective measures for prevention and
treatment strategies.
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